Literature DB >> 21798709

Clinical factors associated with initiation of renal replacement therapy in critically ill patients with acute kidney injury-a prospective multicenter observational study.

Sean M Bagshaw1, Ron Wald, Jim Barton, Karen E A Burns, Jan O Friedrich, Andrew A House, Matthew T James, Adeera Levin, Louise Moist, Neesh Pannu, Daniel E Stollery, Michael W Walsh.   

Abstract

PURPOSE: Our objective was to describe the current practice for initiation of RRT in this population. There is uncertainty regarding the optimal time to initiate renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI).
METHODS: Prospective study of patients receiving RRT in 6 intensive care units (ICUs) at 3 hospitals from July 2007 to August 2008. We characterized factors associated with start of RRT and evaluated their relationship with mortality.
RESULTS: We included 234 patients. RRT was initiated 1 day (0-4) after ICU admission (median [interquartile range]). Median creatinine was 331 μmol/L (225-446 μmol/L), urea 22.9 mmol/L (13.9-32.9 mmol/L), and RIFLE-Failure in 76.9%. Of traditional indications, Pao(2)/Fio(2) < 200 (54.5%) and oliguria (32.9%) were most common. ICU and hospital mortality were 45.3% and 51.9%, respectively. In adjusted analysis, mortality at RRT initiation was associated with creatinine <332 μmol/L (odds ratio [OR] 2.8; 95% confidence interval [CI] 1.5-5.4), change in urea from admission >8.9 mmol/L (OR 1.8; 95% CI, 1.0-3.4), urine output <82 mL/24 hours (OR 3.0; 95% CI, 1.4-6.5), fluid balance >3.0 L/24 hours (OR 2.3; 95% CI, 1.2-4.5), percentage of fluid overload >5% (OR 2.3; 95% CI, 1.2-4.7), 3 or more failing organs (OR 4.5; 95% CI, 1.2-4.2), Sequential Organ Failure Assessment score >14 (OR 2.3; 95% CI, 1.3-4.3), and start 4 days or more after admission (OR 4.3; 95% CI, 1.9-9.5). Mortality was higher as factors accumulated.
CONCLUSION: In ICU patients requiring RRT, there was marked variation in factors that influence start of RRT. RRT initiation with fewer clinical triggers was associated with lower mortality. Timing of RRT may modify survival but requires appraisal in a randomized trial.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21798709     DOI: 10.1016/j.jcrc.2011.06.003

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  21 in total

1.  Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury.

Authors:  Ron Wald; Neill K J Adhikari; Orla M Smith; Matthew A Weir; Karen Pope; Ashley Cohen; Kevin Thorpe; Lauralyn McIntyre; Francois Lamontagne; Mark Soth; Margaret Herridge; Stephen Lapinsky; Edward Clark; Amit X Garg; Swapnil Hiremath; David Klein; C David Mazer; Robert M A Richardson; M Elizabeth Wilcox; Jan O Friedrich; Karen E A Burns; Sean M Bagshaw
Journal:  Kidney Int       Date:  2015-07-08       Impact factor: 10.612

2.  Progression after AKI: Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments.

Authors:  David P Basile; Joseph V Bonventre; Ravindra Mehta; Masaomi Nangaku; Robert Unwin; Mitchell H Rosner; John A Kellum; Claudio Ronco
Journal:  J Am Soc Nephrol       Date:  2015-10-30       Impact factor: 10.121

3.  Selection and Receipt of Kidney Replacement in Critically Ill Older Patients with AKI.

Authors:  Sean M Bagshaw; Neill K J Adhikari; Karen E A Burns; Jan O Friedrich; Josée Bouchard; Francois Lamontagne; Lauralyn A McIntrye; Jean-François Cailhier; Peter Dodek; Henry T Stelfox; Margaret Herridge; Stephen Lapinsky; John Muscedere; James Barton; Donald Griesdale; Mark Soth; Althea Ambosta; Gerald Lebovic; Ron Wald
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-21       Impact factor: 8.237

4.  Which patients benefit from initiation of dialysis for AKI?

Authors:  Neesh Pannu
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

Review 5.  Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference.

Authors:  Rinaldo Bellomo; Claudio Ronco; Ravindra L Mehta; Pierre Asfar; Julie Boisramé-Helms; Michael Darmon; Jean-Luc Diehl; Jacques Duranteau; Eric A J Hoste; Joannes-Boyau Olivier; Matthieu Legrand; Nicolas Lerolle; Manu L N G Malbrain; Johan Mårtensson; Heleen M Oudemans-van Straaten; Jean-Jacques Parienti; Didier Payen; Sophie Perinel; Esther Peters; Peter Pickkers; Eric Rondeau; Miet Schetz; Christophe Vinsonneau; Julia Wendon; Ling Zhang; Pierre-François Laterre
Journal:  Ann Intensive Care       Date:  2017-05-04       Impact factor: 6.925

6.  Fluid overload and mortality are associated with acute kidney injury in sick near-term/term neonate.

Authors:  David J Askenazi; Rajesh Koralkar; Hayden E Hundley; Angela Montesanti; Neha Patil; Namasivayam Ambalavanan
Journal:  Pediatr Nephrol       Date:  2012-12-09       Impact factor: 3.714

Review 7.  [Renal replacement therapy in the intensive care unit].

Authors:  M P Woznowski; L C Rump; G Schieren
Journal:  Internist (Berl)       Date:  2014-11       Impact factor: 0.743

Review 8.  A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis.

Authors:  Constantine J Karvellas; Maha R Farhat; Imran Sajjad; Simon S Mogensen; Alexander A Leung; Ron Wald; Sean M Bagshaw
Journal:  Crit Care       Date:  2011-02-25       Impact factor: 9.097

9.  Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study.

Authors:  Suvi T Vaara; Anna-Maija Korhonen; Kirsi-Maija Kaukonen; Sara Nisula; Outi Inkinen; Sanna Hoppu; Jouko J Laurila; Leena Mildh; Matti Reinikainen; Vesa Lund; Ilkka Parviainen; Ville Pettilä
Journal:  Crit Care       Date:  2012-10-17       Impact factor: 9.097

10.  Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial.

Authors:  Orla M Smith; Ron Wald; Neill K J Adhikari; Karen Pope; Matthew A Weir; Sean M Bagshaw
Journal:  Trials       Date:  2013-10-05       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.